Abiomed Artificial Heart HDE Voted Down By Cardio Panel In Wild Finish
This article was originally published in The Gray Sheet
Executive Summary
Abiomed will give FDA additional anti-coagulation and quality-of-life data from a 14-patient trial supporting the firm's HDE application for the AbioCor total artificial heart, following a negative panel vote